The Use of Plasma Surface-Enhanced Laser Desorption/Ionization Time-of-Flight Mass Spectrometry Proteomic Patterns for Detection of Head and Neck Squamous Cell Cancers

Purpose: Our study was undertaken to determine the utility of plasma proteomic profiling using surface-enhanced laser desorption/ionization time-of-flight (SELDI-TOF) mass spectrometry for the detection of head and neck squamous cell carcinomas (HNSCCs). Experimental Design: Pretreatment plasma samples from HNSCC patients or controls without known neoplastic disease were analyzed on the Protein Biology System IIc SELDI-TOF mass spectrometer (Ciphergen Biosystems, Fremont, CA). Proteomic spectra of mass:charge ratio (m/z) were generated by the application of plasma to immobilized metal-affinity-capture (IMAC) ProteinChip arrays activated with copper. A total of 37,356 data points were generated for each sample. A training set of spectra from 56 cancer patients and 52 controls were applied to the “Lasso” technique to identify protein profiles that can distinguish cancer from noncancer, and cross-validation was used to determine test errors in this training set. The discovery pattern was then used to classify a separate masked test set of 57 cancer and 52 controls. In total, we analyzed the proteomic spectra of 113 cancer patients and 104 controls. Results: The Lasso approach identified 65 significant data points for the discrimination of normal from cancer profiles. The discriminatory pattern correctly identified 39 of 57 HNSCC patients and 40 of 52 noncancer controls in the masked test set. These results yielded a sensitivity of 68% and specificity of 73%. Subgroup analyses in the test set of four different demographic factors (age, gender, and cigarette and alcohol use) that can potentially confound the interpretation of the results suggest that this model tended to overpredict cancer in control smokers. Conclusions: Plasma proteomic profiling with SELDI-TOF mass spectrometry provides moderate sensitivity and specificity in discriminating HNSCC. Further improvement and validation of this approach is needed to determine its usefulness in screening for this disease.

[1]  J. Jen,et al.  Facile detection of mitochondrial DNA mutations in tumors and bodily fluids. , 2000, Science.

[2]  E. Petricoin,et al.  MECHANISMS OF DISEASE Mechanisms of disease Use of proteomic patterns in serum to identify ovarian cancer , 2022 .

[3]  S. Hanash,et al.  Disease proteomics , 2003, Nature.

[4]  T. Yip,et al.  Comprehensive proteomic profiling identifies serum proteomic signatures for detection of hepatocellular carcinoma and its subtypes. , 2003, Clinical chemistry.

[5]  E. Fung,et al.  Proteomic approaches to tumor marker discovery. , 2002, Archives of pathology & laboratory medicine.

[6]  Bao-Ling Adam,et al.  Diagnostic potential of serum proteomic patterns in prostate cancer. , 2003, The Journal of urology.

[7]  L. Sobin,et al.  TNM classification of malignant tumors. A comparison between the new (1987) and the old editions , 1988, Cancer.

[8]  S. Weinberger,et al.  Recent advancements in surface‐enhanced laser desorption/ionization‐time of flight‐mass spectrometry , 2000, Electrophoresis.

[9]  S. Taylor.  Head and neck cancer. , 1991, Cancer chemotherapy and biological response modifiers.

[10]  M. Downer,et al.  An interim determination of health gain from oral cancer and precancer screening: 3. Preselecting high risk individuals. , 1998, Community dental health.

[11]  B. Turlach.  Discussion of "Least Angle Regression" by Efron, Hastie, Johnstone and Tibshirani , 2004 .

[12]  Yu Shyr,et al.  Proteomic patterns of tumour subsets in non-small-cell lung cancer , 2003, The Lancet.

[13]  D. Carter.  TNM Classification of Malignant Tumors , 1998 .

[14]  J. Herman,et al.  Gene promoter hypermethylation in tumors and serum of head and neck cancer patients. , 2000, Cancer research.

[15]  Michael B. Cohen.  Development of a novel proteomic approach for the detection of transitional cell carcinoma of the bladder in urine , 2001 .

[16]  P. Schellhammer,et al.  Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. , 2002, Cancer research.

[17]  D. Chan,et al.  Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. , 2002, Clinical chemistry.

[18]  J. Ferlay,et al.  Estimates of the worldwide incidence of eighteen major cancers in 1985 , 1993, International journal of cancer.

[19]  P. Schellhammer,et al.  Boosted decision tree analysis of surface-enhanced laser desorption/ionization mass spectral serum profiles discriminates prostate cancer from noncancer patients. , 2002, Clinical chemistry.

[20]  R. Tibshirani.  The lasso method for variable selection in the Cox model. , 1997, Statistics in medicine.

[21]  R. Irizarry,et al.  Serum protein MALDI profiling to distinguish upper aerodigestive tract cancer patients from control subjects. , 2003, Journal of the National Cancer Institute.

[22]  Edward S. Kim,et al.  Chemoprevention of aerodigestive tract cancers. , 2002, Annual review of medicine.

[23]  T. Yip,et al.  New desorption strategies for the mass spectrometric analysis of macromolecules , 1993 .

[24]  S. Liu,et al.  Detection of head and neck squamous cell carcinoma among exfoliated oral mucosal cells by microsatellite analysis. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[25]  M. Downer,et al.  An interim determination of health gain from oral cancer and precancer screening: 1. Obtaining health state utilities. , 1997, Community dental health.

[26]  E. Petricoin,et al.  Clinical proteomics: translating benchside promise into bedside reality , 2002, Nature Reviews Drug Discovery.

[27]  D. Ruppert.  The Elements of Statistical Learning: Data Mining, Inference, and Prediction , 2004 .

[28]  P. Pisani,et al.  Early findings from a community‐based, cluster‐randomized, controlled oral cancer screening trial in Kerala, India , 2000, Cancer.

[29]  B. Das,et al.  Oral cancer: reviewing the present understanding of its molecular mechanism and exploring the future directions for its effective management. , 2003, Oral oncology.

[30]  J. Jen,et al.  Promoter hypermethylation patterns of p16, O6-methylguanine-DNA-methyltransferase, and death-associated protein kinase in tumors and saliva of head and neck cancer patients. , 2001, Cancer research.

[31]  Trevor Hastie,et al.  The Elements of Statistical Learning , 2001 .

[32]  E. Petricoin,et al.  Serum proteomic patterns for detection of prostate cancer. , 2002, Journal of the National Cancer Institute.